Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(40.0%)
Phase 2
2(40.0%)
Phase 4
1(20.0%)
5Total
Phase 3(2)
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01870206Phase 3Unknown

Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns

Role: lead

NCT00739440Phase 4Completed

Randomized Controlled Trial to Compare Two Anti-scorpion Serums

Role: lead

NCT01415830Phase 3Completed

Compare Two Anti-Scorpion Venom Serum In Children

Role: lead

NCT01577316Phase 2Unknown

Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women

Role: collaborator

NCT00989274Phase 2Withdrawn

Clinical Trial to Evaluate the Immunogenicity and Safety of the Vaccine Against Influenza A/H1N1

Role: collaborator

All 5 trials loaded